ArticleClinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology2025
Biologic Prescription Patterns and Biomarker Determinants of First-Line Dupilumab in Danish Adult Patients With Severe Asthma and Comorbid Atopic Dermatitis.
Article in Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances and Challenges in the Development of New and Novel Treatment Strategies for Eosinophilic Esophagitis (EoE).Pharmaceuticals (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundAsthma and atopic dermatitis are common type-2 (T2)-driven diseases that often coexist, although different T2 biomarkers indicate disease severity in each condition. Multiple biologics target T2 inflammation, but only dupilumab has been approved for both diseases. Little is known about patients with severe asthma and comorbid atopic dermatitis, particularly regarding how this comorbidity influences the choice of biologic for severe asthma.
methodsWe utilised the nationwide Danish Severe Asthma Register to characterise patients with severe asthma and comorbid atopic dermatitis, and describe prescription patterns of biologics in patients with and without comorbid atopic dermatitis. We compared biomarker determinants of first-line dupilumab prescription between the two groups using a multivariate logistic regression model adjusting for age and sex.
resultsWe identified 1137 patients initiating a biologic for severe asthma, of whom 192 (17%) had comorbid atopic dermatitis. Patients with comorbid atopic dermatitis more often had childhood-onset asthma with an allergic phenotype. The prescription patterns of biologics differed according to comorbid atopic dermatitis status, and patients with comorbid atopic dermatitis were more likely to switch (OR 3.02, p < 0.001). In patients with comorbid atopic dermatitis, elevated IgE was the strongest biomarker determinant of first-line dupilumab prescription (OR 8.77, p < 0.001), whereas in patients without, it was elevated FeNO (OR 1.76, p = 0.03).
conclusionBiologic prescription patterns in severe asthma vary according to comorbid atopic dermatitis status. In patients with comorbid atopic dermatitis, elevated IgE predicts first-line dupilumab prescription, indicating that the severity of atopic dermatitis influences treatment decisions. Additional research is needed to explore the management of coexisting T2 diseases with biological therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.